252 related articles for article (PubMed ID: 28651817)
21. Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?
Chelariu-Raicu A; Coleman RL; Sood AK
Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365748
[TBL] [Abstract][Full Text] [Related]
22. Advances in Anti-Cancer Drug Development: Metformin as Anti-Angiogenic Supplemental Treatment for Glioblastoma.
Shah S; Mansour HM; Aguilar TM; Lucke-Wold B
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891882
[TBL] [Abstract][Full Text] [Related]
23. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition.
Martin L; Schilder R
J Clin Oncol; 2007 Jul; 25(20):2894-901. PubMed ID: 17617520
[TBL] [Abstract][Full Text] [Related]
24. Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.
Duan P; Fan L; Gao Q; Silwal BM; Ren M; Shen Y; Qu W
Curr Drug Targets; 2017; 18(10):1171-1178. PubMed ID: 28443505
[TBL] [Abstract][Full Text] [Related]
25. Targeted anti-vascular therapies for ovarian cancer: current evidence.
Hall M; Gourley C; McNeish I; Ledermann J; Gore M; Jayson G; Perren T; Rustin G; Kaye S
Br J Cancer; 2013 Feb; 108(2):250-8. PubMed ID: 23385789
[TBL] [Abstract][Full Text] [Related]
26. Nintedanib in ovarian cancer.
Khalique S; Banerjee S
Expert Opin Investig Drugs; 2017 Sep; 26(9):1073-1081. PubMed ID: 28721753
[TBL] [Abstract][Full Text] [Related]
27. New drugs in ovarian cancer.
Fleming GF
Clin Adv Hematol Oncol; 2015 Apr; 13(4):223-5. PubMed ID: 26352580
[No Abstract] [Full Text] [Related]
28. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
Minion LE; Tewari KS
Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
[TBL] [Abstract][Full Text] [Related]
29. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.
Eyler CE; Rich JN
J Clin Oncol; 2008 Jun; 26(17):2839-45. PubMed ID: 18539962
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
31. Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).
Marchetti C; Gasparri ML; Ruscito I; Palaia I; Perniola G; Carrone A; Farooqi AA; Pecorini F; Muzii L; Panici PB
Crit Rev Oncol Hematol; 2015 Jun; 94(3):302-10. PubMed ID: 25783620
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
33. Recent advancements of antiangiogenic combination therapies in ovarian cancer.
An D; Banerjee S; Lee JM
Cancer Treat Rev; 2021 Jul; 98():102224. PubMed ID: 34051628
[TBL] [Abstract][Full Text] [Related]
34. A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.
Yin X; Wang X; Shen B; Jing Y; Li Q; Cai MC; Gu Z; Yang Q; Zhang Z; Liu J; Li H; Di W; Zhuang G
Sci Rep; 2016 Aug; 6():31079. PubMed ID: 27498762
[TBL] [Abstract][Full Text] [Related]
35. Biomarkers in the development of anti-angiogenic therapies for ovarian cancer.
Raja FA; Hook JM; Ledermann JA
Cancer Treat Rev; 2012 Oct; 38(6):662-72. PubMed ID: 22209539
[TBL] [Abstract][Full Text] [Related]
36. Targeting angiogenesis in ovarian cancer.
Schmitt J; Matei D
Cancer Treat Rev; 2012 Jun; 38(4):272-83. PubMed ID: 21764518
[TBL] [Abstract][Full Text] [Related]
37. Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer.
Kim TH; Suh DH; Kim MK; Song YS
Biomed Res Int; 2014; 2014():132702. PubMed ID: 25050322
[TBL] [Abstract][Full Text] [Related]
38. Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma.
Yao H; Liu N; Lin MC; Zheng J
Cancer Lett; 2016 Sep; 379(2):213-9. PubMed ID: 27108065
[TBL] [Abstract][Full Text] [Related]
39. Metformin and ovarian cancer survival: is there a rational warrant for belief?
Mormile R
Arch Gynecol Obstet; 2019 Oct; 300(4):797-798. PubMed ID: 31346700
[TBL] [Abstract][Full Text] [Related]
40. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
